Rheumatoid arthritis and cardiovascular diseases: close relatives or friends?
https://doi.org/10.14412/1996-7012-2023-2-16-22
Abstract
The problem of comorbidity is widely discussed in modern medical literature. Its role in rheumatic diseases is of particular interest due to their multifactorial nature and the involvement of a wide range of pathogenetic mechanisms. For many years, researchers around the world have noted correlations between the presence of active autoimmune disorders and the complicated course of cardiovascular diseases. A deeper understanding of the pathogenetic mechanisms at the present stage of development of rheumatology allows us to take a fresh look at the relationship between atherosclerosis and rheumatoid arthritis. The definition of multimorbidity developed in recent years and the results of recent scientific studies may contribute to a more correct choice of tactics for managing patients with a combination of these two diseases.
Keywords
comorbidity,
multimorbidity,
rheumatoid arthritis,
cardiovascular diseases,
atherosclerosis,
autoimmunity,
autoinflammation
Supporting agencies: The investigation has been conducted within scientific topic № 1021051503137-7
About the Authors
A. V. Gordeev
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation
Russian Federation
Russian Federation
Andrey Viktorovich Gordeev
34A, Kashirskoe Shosse, Moscow 115522; 19, Marshala Timoshenko Street, Build. 1A, Moscow 121359
Yu. A. Olyunin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. A. Galushko
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. G. Zotkin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology Russian MACPE.
34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019 Nov;78(11):1463-71. doi: 10.1136/annrheumdis-2019-215920.
2. Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021 May;41(5):863-77. doi: 10.1007/s00296-020-04731-0.
3. Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. Incidence of diseases of the musculoskeletal system in the Russian Federation for 2015-2016. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15-21. (In Russ.).
4. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801-6. doi: 10.7326/0003-4819-117-10-801.
5. Lundstrom E, Källberg H, Alfredsson L, et al. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 2009 Jun;60(6): 1597-603. doi: 10.1002/art.24572.
6. Deane KD, O’Donnell CI, Hueber W, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an agedependent manner. Arthritis Rheum. 2010 Nov; 62(11):3161-72. doi: 10.1002/art.27638.
7. Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis. 2008 Dec;67 Suppl 3(Suppl 3):iii30-4. doi: 10.1136/ard.2008.098038.
8. Safiri S, Kolahi AA, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017. Arthritis Rheumatol. 2021 Apr;73(4):702-14. doi: 10.1002/art.41571.
9. Widdifield J, Bernatsky S, Paterson JM, et al. Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada. Arthritis Care Res (Hoboken). 2015 Aug; 67(8):1047-53. doi: 10.1002/acr.22553.
10. Van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017 Apr;37(4):487-93. doi: 10.1007/s00296-016-3638-5.
11. Holmqvist M, Ljung L, Askling J. Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact? Ann Rheum Dis. 2018 Jan;77(1):85-91. doi: 10.1136/annrheumdis-2017-212131.
12. Popkova TV, Novikova DS, Nasonov EL. Cardiovascular diseases in rheumatoid arthritis: new data. Nauchno-prakticheskaya revmatologiya. 2016;54(2):122-8. (In Russ.).
13. Mutovina ZYu, Zagrebneva AI, Galushko EA, Gordeev AV. Cardiorenal syndrome in patients with rheumatoid arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(3):82-6. (In Russ.). doi: 10.14412/1996-7012-2019-3-82-86
14. Gorbunova YuN, Novikova DS, Popkova TV, et al. Cardiovascular risk in patients with early rheumatoid arthritis before the appointment of basic anti-inflammatory therapy (preliminary data of the REMARK study). Nauchnoprakticheskaya revmatologiya. 2014;52(4): 381-6. (In Russ.).
15. Vaisman DSh, Sorotskaya VN, Nikitina ES. Analysis of mortality from diseases of the musculoskeletal system for initial and multiple causes in residents of the Tula region. Nauchno-prakticheskaya revmatologiya. 2017; 55(6):616-20. (In Russ.).
16. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005 Mar;52(3):722-32. doi: 10.1002/art.20878.
17. Novikova DS, Popkova TV, Gerasimov AN, et al. Painless myocardial ischemia and cardiac arrhythmias in women with rheumatoid arthritis. Klinitsist. 2013;(3-4):31-40. (In Russ.).
18. Popkova TV, Novikova DS, Nasonov EL. Atherosclerosis in rheumatic diseases. In: Nasonov EL, editor. Revmatologiya: klinicheskie rekomendatsii [Rheumatology: clinical guidelines]. Moscow: GEOTAR-Media; 2010. P. 678-702.
19. Novikova DS, Popkova TV, Mach ES, Nasonov EL. Determination of calcium in coronary arteries: new opportunities for stratification of the risk of cardiovascular complications in patients with autoimmune diseases. Nauchnoprakticheskaya revmatologiya. 2009;47(3): 60-6. (In Russ.).
20. Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis. 2012 Oct;71(10): 1606-15. doi: 10.1136/annrheumdis-2012201334. Epub 2012 Jun 26.
21. Novikova DS, Popkova TV, Gerasimov AN, et al. The relationship of cardiovascular risk factors with arterial wall rigidity in women with high activity of rheumatoid arthritis. Ratsional'naya farmakoterapiya v kardiologii. 2012; 8(6):756-65. (In Russ.).
22. Kirillova IG, Novikova DS, Popkova TV, et al. Diastolic dysfunction of the left and right ventricles in patients with early rheumatoid arthritis before the appointment of basic antiinflammatory therapy. Terapevticheskii arkhiv. 2015;87(5):16-23. (In Russ.).
23. Nasonov EL, Popkova TV. Anti-inflammatory therapy of atherosclerosis – contribution and lessons of rheumatology. Nauchno-prakticheskaya revmatologiya. 2017;55(5):465-73. (In Russ.).
24. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016 Jan 8;118(1):145-56. doi: 10.1161/CIRCRESAHA.115.306656.
25. Gerasimova EV, Popkova TV. Functional disorders of macrophages in rheumatoid arthritis and atherosclerosis. Nauchno-prakticheskaya revmatologiya. 2018;56(4):486-93. (In Russ.).
26. Lopez-Mejias R, Genre F, Corrales A, et al. Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2014 Sep;73(9): 1749-50. doi: 10.1136/annrheumdis-2014205543
27. Ibrahim I, Humphreys J, Mokhtar I, et al. Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2015 Nov;74(11):2099102. doi: 10.1136/annrheumdis-2015-207851
28. Lee YH, Bae SC. Monocyte chemoattractant protein-1 promoter -2518 polymorphism and susceptibility to vasculitis, rheumatoid arthritis, and multiple sclerosis: A meta-analysis. Cell Mol Biol (Noisy-le-grand). 2016 Mar 20;62(3):65-71.
29. Leonard D, Svenungsson E, Dahlqvist J, et al. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2018 Mar 7. pii: annrheumdis-2017-212614. doi: 10.1136/annrheumdis-2017-212614
30. Popkova TV, Novikova DS, Pisarev VV, et al. Risk factors for cardiovascular diseases in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2009;(3):4-11. (In Russ.).
31. Кондратьева ЛВ, Попкова ТВ, Насонов ЕЛ. Метаболический синдром при ревматоидном артрите. Научно-практическая ревматология. 2013;51(3):302-12. [Kondrat'eva LV, Popkova TV, Nasonov EL. Metabolic syndrome in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2013; 51(3):302-12. (In Russ.)].
32. Nasonov EL. Methotrexate for rheumatoid arthritis – 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya. 2015;53(4): 421-33. (In Russ.).
33. Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22(16):1903-10. doi: 10.2174/0929867322666150415122039.
34. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-31. doi: 10.1056/NEJMoa1707914.
35. Nasonov EL, Eliseev MS. The role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya. 2016;54(1):60-77. (In Russ.).
36. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938.
37. Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010 Jul 23;5(7): e11765. doi: 10.1371/journal.pone.0011765.
38. Xiao H, Lu M, Lin TY, et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013 Aug 6;128(6): 632-42. doi: 10.1161/CIRCULATIONAHA.113.002714. Epub 2013 Jul 9.
39. Folco EJ, Sukhova GK, Quillard T, Libby P. Moderate hypoxia potentiates interleukin-1 production in activated human macrophages. Circ Res. 2014 Oct 24;115(10):875-83. doi: 10.1161/CIRCRESAHA.115.304437. Epub 2014 Sep 2.
40. Fedorov ES, Salugina SO, Kuz'mina NN. Development of the doctrine of autoinflammatory diseases in the XXI century. Nauchnoprakticheskaya revmatologiya. 2018;56:5-18. (In Russ.).
41. Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 Feb 21;380(8):752-62. doi: 10.1056/NEJMoa1809798.
42. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord. 2011 Jul 7;12:153. doi: 10.1186/14712474-12-153.
43. Udachkina EV, Novikova DS, Popkova TV, et al. Progression of atherosclerosis of the carotid arteries in patients with early rheumatoid arthritis against the background of anti-rheumatic therapy conducted on the principle of "Treatment until the goal is achieved". Nauchno-prakticheskaya revmatologiya. 2018;56(4):449-55. (In Russ.).
44. Fomicheva OA, Popkova TV, Krougly LB, et al. Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis. Kardiologiya. 2021;61(1):12-21. (In Russ.).
45. Gerasimova EV, Popkova TV, Novikova DS, et al. Risk factors of coronary artery stenosis in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya. 2017; 55(6):628-33 (In Russ.).
46. Каратеев ДЕ, Олюнин ЮА. О классификации ревматоидного артрита. Научнопрактическая ревматология. 2008;46(1):5-16. [Karateev DE, Olyunin YuA. About the classification of rheumatoid arthritis. Nauchnoprakticheskaya revmatologiya. 2008;46(1):5-16. (In Russ.)].
47. Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 2014;16(3):114. doi: 10.1186/ar4593.
48. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-79. doi: 10.1136/annrheumdis-2021-221733.
49. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775.
Review
For citations:
Gordeev AV, Olyunin YA, Galushko EA, Zotkin EG, Lila AM. Rheumatoid arthritis and cardiovascular diseases: close relatives or friends? Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(2):16-22. (In Russ.) https://doi.org/10.14412/1996-7012-2023-2-16-22
Views:
861
Email this article 